Accelerated Cure Project MS Repository
Accelerated Cure Project for Multiple Sclerosis
http://www.acceleratedcure.org
Repository Web site
https://www.acceleratedcure.org/repository/index.php
Primary contact
Hollie Schmidt, VP of Scientific Operations
300 5th Avenue, Waltham, MA 02451
Tel 1-781-487-0099
Sample types available
DNA
Serum
Plasma
RNA
Peripheral blood mononuclear cells
Longitudinal sample collections
Prospective collections to meet specific sample or subject requirements
Sample-processing information
https://www.acceleratedcure.org/repository/sampleprocessing.php
Each sample type has its own processing procedure. Details can be found at the above link.
Data available for each sample
Case Report Form on each subject that includes demographic information, environmental exposure information, personal and family medical history, and diagnosis details.
Quantity of available samples
As of March 2012, there are samples available from 2942 participants: 1741 from people with MS, 559 from people with other demyelinating disorders, and 642 from controls. In addition, longitudinal samples and data are available for 387 participants (326 people with MS and 61 people with other demyelinating disorders).
Who can request samples
Anyone.
Cost
Cost information can be found at: http://www.acceleratedcure.org/repository/downloads/ACP_Cost_Recovery_Policy.pdf
How to request samples
If you are interested in requesting samples and/or data from the ACP Repository, we ask that you submit a written proposal describing the type and amount of samples needed, the planned research, details regarding the data that will be returned to the repository, status of IRB approval and funding, etc. We encourage you to request as many samples as you feel are necessary to produce a valid conclusion for your investigation.
This proposal will be reviewed by Accelerated Cure Project staff for completeness, alignment with the purpose of the repository, and our ability to fulfill the request. You will be notified of any issues and given the opportunity to submit changes.
After preliminary review, the proposal will be further reviewed by our Repository Oversight Committee, which will make a recommendation on whether to grant your request. Factors that are weighed during this evaluation process include:
- Potential benefit to people with MS and/or related demyelinating diseases.
- Scientific merit of the proposal.
- Adequacy of the plans for contributing data back to the repository.
Oversight committee reviews take place bimonthly; proposals are sent to committee members on the first business day of January, March, May, July, September, and November. We recommend that you send your proposal to Accelerated Cure Project 2 weeks or more before the next distribution date in order to be included in that review cycle.
Accelerated Cure Project will make a final decision on providing the samples and data to you. If we are unable to meet your needs, we will attempt to identify an alternate resource for you.
You can find additional details of the application process at
https://www.acceleratedcure.org/repository/downloads/ACP_Sample_Request.doc
Requirements associated with sample use
A written proposal must be submitted and approved by the Repository Oversight Committee. Once the study is complete, the researcher is required to return the results of his/her research to ACP so that other researchers may utilize the data.
Ongoing sample collection?
Yes.
Sample Publications
For a list of research studies supported by this repository, see https://www.acceleratedcure.org/repository/research.php.
Stüve O, Wang J, Chan A, Hemmer B, Cepok S, Nessler S, Zipp F, Goldman MD, Meuth SG, Korth C, Lambracht-Washington D.
Arch Neurol. 2011 Feb;68(2):264-5. PMID: 21320996
Gene-expression signatures: biomarkers toward diagnosing multiple sclerosis.
Tossberg JT, Crooke PS, Henderson MA, Sriram S, Mrelashvili D, Chitnis S, Polman C, Vosslamber S, Verweij CL, Olsen NJ, Aune TM.
Genes Immun. 2012 Feb;13(2):146-54. doi: 10.1038/gene.2011.66. Epub 2011 Sep 22. PMID: 21938015
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis.
International Multiple Sclerosis Genetics Consortium and Wellcome Trust Case Control Consortium 2.
Nature. 2011 Aug 10;476(7359):214-9. doi: 10.1038/nature10251. PMID: 21833088
Genetics and the environment converge to dysregulate N-glycosylation in multiple sclerosis.
Mkhikian H, Grigorian A, Li CF, Chen HL, Newton B, Zhou RW, Beeton C, Torossian S, Tatarian GG, Lee SU, Lau K, Walker E, Siminovitch KA, Chandy KG, Yu Z, Dennis JW, Demetriou M.
Nat Commun. 2011;2:334. PMID: 21629267
Genetic variation in the IL7RA/IL7 pathway increases multiple sclerosis susceptibility.
Zuvich RL, McCauley JL, Oksenberg JR, Sawcer SJ, De Jager PL; International Multiple Sclerosis Genetics Consortium, Aubin C, Cross AH, Piccio L, Aggarwal NT, Evans D, Hafler DA, Compston A, Hauser SL, Pericak-Vance MA, Haines JL.
Hum Genet. 2010 Mar;127(5):525-35. Epub 2010 Jan 30. PMID: 20112030
De Jager PL, Jia X, Wang J, de Bakker PI, Ottoboni L, Aggarwal NT, Piccio L, Raychaudhuri S, Tran D, Aubin C, Briskin R, Romano S; International MS Genetics Consortium, Baranzini SE, McCauley JL, Pericak-Vance MA, Haines JL, Gibson RA, Naeglin Y, Uitdehaag B, Matthews PM, Kappos L, Polman C, McArdle WL, Strachan DP, Evans D, Cross AH, Daly MJ, Compston A, Sawcer SJ, Weiner HL, Hauser SL, Hafler DA, Oksenberg JR.
Nat Genet. 2009 Jul;41(7):776-82. Epub 2009 Jun 14. PMID: 19525953
IL12A, MPHOSPH9/CDK2AP1 and RGS1 are novel multiple sclerosis susceptibility loci.
International Multiple Sclerosis Genetics Consortium (IMSGC).
Genes Immun. 2010 Jul;11(5):397-405. Epub 2010 Jun 17. PMID: 20555355
International Multiple Sclerosis Genetics Consortium (IMSGC).
Hum Mol Genet. 2010 Mar 1;19(5):953-62. Epub 2009 Dec 9. PMID: 20007504
Genetic analysis of aquaporin-4 in neuromyelitis optica.
Matiello M, Schaefer-Klein JL, Hebrink DD, Kingsbury DJ, Atkinson EJ, Weinshenker BG; NMO Genetics Collaborators.
Neurology. 2011 Sep 20;77(12):1149-55. Epub 2011 Sep 7. PMID: 21900637
HLA-DRB1*1501 tagging rs3135388 polymorphism is not associated with neuromyelitis optica.
Matiello M, Schaefer-Klein J, Brum DG, Atkinson EJ, Kantarci OH, Weinshenker BG; NMO genetics collaborators.
Mult Scler. 2010 Aug;16(8):981-4. Epub 2010 Jun 30. PMID: 20591987
Vyshkina T, Sylvester A, Sadiq S, Bonilla E, Canter JA, Perl A, Kalman B.
Clin Immunol. 2008 Oct;129(1):31-5. Epub 2008 Aug 16. PMID: 18708297
CCL genes in multiple sclerosis and systemic lupus erythematosus.
Vyshkina T, Sylvester A, Sadiq S, Bonilla E, Perl A, Kalman B.
J Neuroimmunol. 2008 Aug 30;200(1-2):145-52. Epub 2008 Jul 3. PMID: 18602166